Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1017 participants
OBSERVATIONAL
2020-09-21
2025-05-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
All patients who were supported retrospectively (prior to site IRB approval) with Impella 5.5 at the investigative site will be entered into the SURPASS registry and specified as the retrospective cohort.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery
NCT00554359
A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.
NCT05524051
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants
NCT05291546
Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury
NCT05507437
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT05510115
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single arm all comers supported with Impella 5.5
Impella 5.5
Impella 5.5 mechanical circulatory support
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Impella 5.5
Impella 5.5 mechanical circulatory support
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has previously undergone an Impella 5.5 implant at a study site
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abiomed Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Masaki Funamoto, MD
Role: PRINCIPAL_INVESTIGATOR
Methodist San Antonio Hospital
Mark Anderson, MD
Role: PRINCIPAL_INVESTIGATOR
Hackensack Meridian Health
David D'Alessandro, MD
Role: PRINCIPAL_INVESTIGATOR
MGH
Gundars Katlaps, MD
Role: PRINCIPAL_INVESTIGATOR
Tampa General Hospital
Anthony Lemaire, MD
Role: PRINCIPAL_INVESTIGATOR
Robert Wood Johnson University Hospital
Edward Soltesz, MD
Role: PRINCIPAL_INVESTIGATOR
The Cleveland Clinic
Masashi Kawabori, MD
Role: PRINCIPAL_INVESTIGATOR
Tufts Medical Center
Ahmad Zeeshan, MD
Role: PRINCIPAL_INVESTIGATOR
Advent Health Orlando
Fardad Esmailian, MD
Role: PRINCIPAL_INVESTIGATOR
Cedars-Sinai Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cedars Sinai Medical Center
Los Angeles, California, United States
Advent Health Orlando
Orlando, Florida, United States
Tampa General Hospital
Tampa, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
Northwestern University
Evanston, Illinois, United States
Tufts Medical Center
Boston, Massachusetts, United States
MGH
Boston, Massachusetts, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
The Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States
Cleveland Clinic
Cleveland, Ohio, United States
Integris Health Baptist Medical Center
Oklahoma City, Oklahoma, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Memorial Hermann Texas Medical Center
Houston, Texas, United States
Methodist San Antonio Hospital
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Surpass
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.